http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101925356-B

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a98cb1b197f761c87cd3caf32bc247e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7e9aee13868bfedebe2df1f13cda5490
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-282
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4412
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1271
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1272
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-555
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-282
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4412
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513
filingDate 2009-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2014-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b25bb70f7463d54ddc411bdd69febd7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39e97a6a30115a91aa0519ae86472f4b
publicationDate 2014-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-101925356-B
titleOfInvention Agent for enhancing anti-tumor effect comprising oxaliplatin liposome preparation, and anti-tumor agent comprising liposome preparation
abstract The object is to further enhance the anti-tumor effect when oxaliplatin is used in combination with a mixed preparation containing tegafur, gimeracil and oteracil potassium. By using oxaliplatin in the form of a liposome preparation, when the liposome preparation is used in combination with a mixed preparation containing tegafur, gimeracil and oteracil potassium, the anti-tumor effect can be significantly enhanced without increasing adverse side effects.
priorityDate 2008-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007099377-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454411087
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419505489
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6138
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454051202
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507953
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415133005
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID105166
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID74257205
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID2029523
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419583147
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419551227
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419504160
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415794038
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60953
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID168614
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID94190
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID887
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID452178732
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419485703
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414856775
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21911965
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135403648
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6857599
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID452110
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54679224
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5997
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID288216
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419494177
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419577911
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4604
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419521634
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID2029523
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419494593
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID137231040

Total number of triples: 67.